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AbstrACt
Introduction Chronic obstructive pulmonary disease 
(COPD) exacerbations progress the course of disease and 
impair lung function. Inhaled maintenance therapy reduces 
exacerbations. It is not yet established which inhaled 
therapy combination is best to reduce exacerbations, lung 
function decline and symptom burden.
Methods and analysis MEDLINE, EMBASE and the 
Cochrane Library will be searched for articles between 
January 2011 and May 2018 using a pre-specified search 
strategy. Conference proceedings will be searched. 
Systematic reviews (with or without meta-analysis), 
randomised controlled trials (RCTs), cohort studies and 
case controlled studies comparing six interventions 
comprising different combinations of long-acting 
bronchodilators and inhaled corticosteroids in unison or 
on their own. The primary outcome is the reduction in 
moderate-to-severe exacerbations. Secondary outcomes 
include: lung function, quality of life, mortality and other 
adverse events. Titles and abstracts will screened by the 
primary researcher. A second reviewer will repeat this 
on a proportion of records. The Population, Intervention, 
Comparator, Outcomes and Study framework will be used 
for data extraction. A network meta-analyses of outcomes 
from RCTs and real-world evidence will be integrated if 
feasible. The 95% credible interval will be used to assess 
the statistical significance of each summary effect. 
Ranking of interventions will be based on their surface 
under cumulative ranking area.
Ethics and dissemination COPD exacerbations are 
burdensome to patients. We aim to report results that 
provide clinicians with a more informed choice of 
which inhaled therapy combinations are best to reduce 
exacerbations, improve disease burden and reduce lung 
function and exercise capacity decline, compared with the 
potential harms, in certain populations with COPD.
PrOsPErO registration number CRD42018088013.
bACkgrOund
rationale
Chronic obstructive pulmonary disease 
(COPD) affects around 174 million persons 
worldwide.1 The most common cause is 
smoking, and patients exhibit airflow obstruc-
tion that is not fully reversible. The disease 
is progressive, with declining lung function 
and a worsening of symptoms. Most trouble-
some are acute exacerbations manifested as a 
sudden worsening of symptoms, for example, 
severe coughing, shortness of breath and 
chest congestion, requiring urgent treat-
ment and possibly hospitalisation. While 
smoking cessation remains the most effec-
tive intervention, the rate of exacerbation 
can be reduced by regular medication such 
as combination of long-acting beta-adreno-
ceptor agonists (LABAs),2 and inhaled corti-
costeroids (ICS)3 4 or long-acting muscarinic 
antagonists (LAMAs).5 
COPD treatment guidelines are largely 
informed by randomised controlled trial 
(RCT) results,6 but we do not know if these 
findings apply to large patient populations 
not studied in trials. While RCTs will continue 
to be the gold standard for assessing the effi-
cacy of medical interventions, they are expen-
sive to conduct, and for practical and ethical 
strengths and limitations of this study
 ► The planned systematic literature review and 
network meta-analysis will evaluate both ran-
domised  controlled trials and real-world evidence 
in order to reflect the current best evidence-based 
practice and increase the application to a potentially 
heterogeneous group of patients with COPD.
 ► A ranking system of all inhaled treatment compari-
sons will enable clinicians to judge each intervention 
on their evidence of clinical benefit compared with 
their potential harms.
 ► It may not be possible to combine both randomised 
controlled trials and other study designs in a single 
network meta-analysis.
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reasons usually involve testing treatments in patient 
populations and within contexts which are sometimes 
very different from real life. In particular, RCT partici-
pants with COPD usually have no comorbidities and are 
otherwise healthy. Whereas often the very patients who 
are most commonly seen in a COPD outpatient clinic are 
those that would be excluded from clinical trials due to 
their comorbidities. As patient populations with chronic 
diseases such as COPD become more complex, the studies 
used to generate clinical evidence must reflect this.
Evidence of medication effects in routine care is vital 
for understanding the balance of treatment risks and 
benefits. RCTs have unique strengths, but results from 
trials are not always a good guide to the effects of drugs in 
routine clinical practice.7 National drug licensing author-
ities are now demanding better real-world evidence on 
which to make decisions and have introduced legislation 
mandating studies of both effectiveness and risk to be 
conducted in routine clinical care rather than the narrow 
and optimal confines of most randomised trials.8 9 While 
the conduct of observational studies to investigate 
possible drug harms is well established, the use of these 
studies to estimate treatment effectiveness is in its infancy. 
Issues of treatment channelling and indication bias mean 
that measuring the intended benefit of a treatment is 
beset with difficulties. While others have demonstrated 
it can be done in certain circumstances, we need more 
certainty about the methodology as it is applied in each 
disease area, since the issues of bias are likely to vary 
considerably.9
There is increasing evidence that dual long-acting bron-
chodilator therapy (LABA+LAMA) is more clinically bene-
ficial compared with monotherapy or placebo10; however, 
there is also evidence that adding an ICS to LABA and 
LABA as triple therapy is better at reducing exacerbations 
and maintaining lung function.11 Furthermore, new treat-
ments for reducing exacerbation frequency have become 
more evidenced based in recent years with commonly 
inhaled therapies (LABAs, LAMAs, ICS and combination 
devices) being prescribed alongside other treatments 
such as mucolytics (carbocysteine, N-acetylcysteine),12 
antibiotics (macrolides) and inhaled colomycin13 14 and 
phosodiesterase-4 inhibitors such as roflumilast.15
Until recently, dual combination therapy (LABA+ICS) 
was the recommended treatment for highly symptomatic 
COPD patients at risk of exacerbations or severe airflow 
limitation.16 However, in the Global Initiative for Chronic 
Obstructive Lung Disease (GOLD) guidelines (2017)17 
triple therapy (combined LABA+LAMA+ ICS) is only 
recommended for patients categorised as severe. Given 
this changing landscape, and the future launch of combi-
nation triple therapies, it is important to identify and 
synthesise the available evidence from clinical trials and 
observational studies.
Objectives
This systematic literature review will assess clinical bene-
fits and adverse events from maintenance treatment 
combinations in COPD described by RCTs and real-
world evidence (RWE) studies. A network meta-analyses 
of outcomes from RCTs and RWE will be integrated if 
feasible.
The primary research question is: What are the clin-
ical benefits of maintenance treatment combinations in 
COPD in terms of reducing exacerbations?
Secondary research questions include:
1. What is the long-term effectiveness of treatment com-
binations on improving lung function as measured by 
forced expiratory volume in 1 s (FEV1)?
2. What is the long-term effectiveness of treatment com-
binations in improving patient-reported outcomes of 
respiratory-related quality of life, as measured by the 
St Georges Respiratory Questionnaire or the COPD 
Assessment Test?
3. What are the harms of each treatment combination in-
cluding mortality, cardiovascular events, pneumonia, 
diabetes and bone fractures?
MEthOds
This protocol has been prepared using the Preferred 




Target studies will include RCTs, cohort studies and case–
control studies comparing each intervention of interest 
to any of the possible comparators and looking at any of 
the possible outcomes (see below and table 1). We will 
also use summary papers, systematic reviews and other 
analyses to source relevant primary papers.
Participants
Adults diagnosed with COPD defined by a fixed post-bron-
chodilator ratio of forced expiratory volume in 1 s to 
forced vital capacity (FEV1/FVC) of less than 0.70. Other 
measures of impaired lung function, such as lower limit 
of normal of FEV1/FVC ratio, will not be used to judge 
diagnosis in this review. The population will be clinically 
stable at the time of recruitment, defined as not having 
been treated for an exacerbation in the prior 6 weeks.
Interventions
There are six interventions of interest: (1) LABA, (2) 
LAMA, (3) LABA+LAMA, (4) ICS, (5) LABA+ICS and (6) 
LABA+LAMA +  ICS.
Comparators
Each intervention may be compared against each other 
intervention or a placebo (table 1).
Outcome
The primary outcome of interest is the number of moder-
ate-to-severe exacerbations experienced by patients 
following intervention. Secondary outcomes include 
FEV1 change from baseline, mortality (all-cause and 
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respiratory-related), respiratory-related quality of life as 
measured by the St Georges Respiratory Questionnaire 
(SGRQ) or the COPD Assessment Tool (CAT) and the 
number of adverse and serious adverse events following 
intervention including cardiovascular events, pneu-
monia, diabetes and bone fractures.
Information sources
MEDLINE (Ovid interface, 1980 onwards) and Embase 
(Ovid interface, 1980 onwards) will be searched for 
potentially relevant articles using pre-defined search strat-
egies. The International Prospective Register of System-
atic Reviews (PROSPERO) will be searched periodically 
for relevant ongoing and completed systematic reviews. 
A manual search of the reference lists of all included 
studies will be conducted to check for other possibly rele-
vant articles.
Manual searches will also be conducted to capture 
data not reported in the main publications and data 
from recent studies not yet published. Manual searches 
are anticipated to include conferences of interest and 
proceedings published from 2015 onwards, based on the 
assumption that trials are usually published within 2 to 
3 years following presentation to a conference. In addi-
tion, we will search agencies’ websites (National Institute 
for Health and Care Excellence etc) and clinical trial 
registry  clinicaltrials. gov.
Studies will be excluded if they investigate only single 
short-acting inhaled therapy versus placebo. Additionally, 
studies will be excluded if they exclude patients on the 
basis of comorbidities that are unlikely to be affected by 
the trialled drug.
search strategy
The list of proposed search terms (table 2) will be reviewed 
by the primary and secondary reviewer and research 
group lead. The final search strategy will be checked 
for accuracy by the guarantor using the Peer Review of 
Electronic Search Strategies (PRESS) checklist.19 The 
search strategy will be developed in the first instance for 
MEDLINE and then adapted for use with Embase. Search 
filters limiting to studies published in 1980 onwards, 
studies published in English and studies in humans will 
be used. The disease terms, inhaler terms and outcome 
searches will be combined using the Boolean logic oper-
ator AND, while different choices of terms within these 
categories using will be combined using OR. The liter-




Literature search results will be uploaded and stored in 
EndNote (X8) and duplicates will be removed.
Selection process
The selection of studies for inclusion in the review will 
be conducted in two stages. First, titles and abstracts 
of all records identified by the database searches will 
screened by the primary researcher against the pre-de-
fined eligibility criteria in order to identify a subset 
of potentially relevant studies. A second reviewer will 
repeat this exercise on a proportion of records and any 
discrepancies resolved by discussion. To reduce the risk of 
missing potentially relevant studies, a deliberately lenient 
approach will be adopted for this first level of screening 
by title and abstract.
We will obtain full reports for all titles that appear to 
meet our eligibility criteria, or where there is uncertainty. 
Full text screening will be also conducted by the primary 
researcher. Supplementary material will be consulted if 
the information provided in the main published article is 
insufficient to assess whether or not the inclusion criteria 
are met. Any discrepancies will be resolved by discussion 
and/or consultation with a third reviewer with specific 
expertise in COPD. A record will be kept of the reasons 
Table 1 Summary of participants, intervention, 
comparators and outcomes (PICO) criteria
Participants: Adults diagnosed with COPD defined by a fixed post-
bronchodilator FEV1/FVC ratio of less than 0.70.
Interventions Comparators Outcomes




e. LABA+LAMA + ICS
f. Placebo
1. Number of moderate-to-
severe exacerbations




quality of life (SGRQ, 
CAT)











e. LABA+LAMA + ICS
f. Placebo




e. LABA+LAMA + ICS
f. Placebo




e. LABA+LAMA + ICS
f. Placebo














COPD, chronic obstructive pulmonary disease; CAT, COPD Assessment 
Tool; FEV1, forced expiratory volume in 1s; FVC, forced vital capacity; ICS, 
inhaled corticosteroids; LABA, long-acting beta-adrenoceptor agonist; 
LAMA, long-acting muscarinic antagonists; SGRQ, St Georges Respiratory 
Questionnaire.
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for rejection of articles during the full-text screening 
process.
Data extraction
Information will be extracted from all selected studies 
using a pre-specified data extraction form. The form will 
be piloted on the first six selected studies and refined 
as necessary. Online supplementary material will be 
consulted and/or authors contacted if the information 
provided in the original published articles is insufficient 
to complete the extraction.
As with screening, data extraction will be carried out 
in duplicate on a proportion of selected records to 
reduce the risk of errors and introducing bias. Similarly, 
any discrepancies will be resolved by discussion and/or 
consultation with the third reviewer.
data items
We will use the PICOs (Population, Intervention, Compar-
ator, Outcomes and Study characteristics) framework to 
systematise our data extraction. Within each of these five 
domains, information will be recorded on the following 
items:
 ► The study characteristics including setting, design, 
period of study, aims and objectives.
 ► The population including characteristics (including 
size, sex and age distribution, ethnicity, country), 
recruitment and sampling methods, inclusion/exclu-
sion criteria.
 ► The intervention status definition and identification, 
number of exposed subjects, any exclusions.
 ► The comparators’ identification and definition 
of unexposed individuals, number of unexposed 
subjects, any exclusions.
 ► The outcomes definitions and identification of 
primary (exacerbation) and secondary outcomes 
(FEV1 change from baseline, mortality, respirato-
ry-related quality of life, adverse events), number of 
subjects, any exclusions, length of follow-up.
Outcomes and prioritisation
The following list of endpoints is anticipated; to protect 
against study selection bias for the length of studies, we 
anticipate splitting our analyses of exacerbations and 
lung function by length of study.
1. Number of moderate-to-severe exacerbations
a. Short-term treatment (<20 weeks)
b. Long-term treatment (≥20 weeks)




MeSH terms: exp Pulmonary Disease, 
Chronic Obstructive/
Free text terms: COPD, chronic 
obstructive pulmonary disease
LABA Free text terms: arformoterol, 
formoterol, indacaterol, olodaterol, 
salmeterol, foradi, vilanterol, onbrez, 
oxis, salmeterol, tulobuterol, vilanterol, 
bambuterol, bambec, atimos 
modulate, striverdi respimat, serevent, 
relvar ellipta
LAMA Free text terms: aclidinium bromide, 
glycopyrronium bromide, tiotropium, 
umeclidinium, anoro ellipta, eklira, 
seebri, Spiriva, incruse, antimuscarinic 
bronchodilators, glycopyrrolate
ICS Free text terms: beclomethasone, 
budesonide, fluticasone furoate, 
fluticasone propionate, fluticasone, 
mometasone furoate, alvesco, 
betamethasone, ciclesonide, flixotide, 
pulmicort, becloforte, becotide, relvar 
ellipta
Exacerbation MeSH terms: exp respiratory tract 
infections/
Free text terms: exacerbation, 
AECOPD, lower respiratory tract 
infection, LRTI
FEV1 Forced expiratory volume in 1 s (FEV1)
Mortality MeSH terms: exp Mortality/exp death/
Free text terms: mortality, death
Quality of life MeSH terms: exp quality of life/
Free text terms: quality of life, St 
Georges Respiratory Questionnaire 
(SGRQ), COPD Assessment Test (CAT)
Myocardial 
Infarction
MeSH terms: exp myocardial 
infarction/
Free text terms: myocardial infarction 
(MI)
Stroke MeSH terms: exp stroke/
Free text terms: stroke
Arrhythmias MeSH terms: exp arrhythmias, cardiac/
exp atrial fibrillation/
Free text terms: arrhythmia, atrial 
fibrillation
Angina MeSH terms: exp angina, unstable/
exp angina pectoris
Free text terms: unstable angina, 
angina pectoris
Pneumonia MeSH terms: exp pneumonia/
Free text terms: pneumonia
Type-2 Diabetes MeSH terms: exp diabetes mellitus, 
type 2/




Fractures MeSH terms: exp osteoporotic 
fractures/exp fractures, bone
Free text terms: osteoporotic fractures, 
bone fractures
ICS, inhaled corticosteroids; LABA, long-acting beta-adrenoceptor 
agonist; LAMA, long-acting muscarinic antagonists.
Table 2 Continued 
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2. FEV1 change from baseline
a. Short-term treatment (<12 weeks)
b. Long-term treatment (≥12 weeks)
3. Mortality
4. Respiratory-related quality of life (SGRQ, CAT)






risk of bias assessment
The primary reviewer will assess the risk of bias of each 
study included using the seven-item Cochrane Risk of Bias 
Tool.20 The Critical Appraisal Skills Programme21 quality 
assessment tools will be used to assess the quality of obser-
vational studies. Risk of bias assessment will be conducted 
independently by a second reviewer on a quarter of the 
selected studies and disagreements will be resolved in the 
first instance by discussion and then through consulta-
tion with a third reviewer. On completion of this process, 
the remaining studies will be assessed for the risk of bias 
by one reviewer. The Alternative Regression Test22 will be 
applied to evidence to test for publication bias.
data synthesis
Three key aspects in the assessment of feasibility of 
network meta-analysis (NMA) (RCTs, RWE) will be 
examined:
1. The validity of an NMA of RCTs may be compromised 
by looking at: (1) clinical heterogeneity, defined as the 
extent of confounding bias due to an RCT’s similari-
ty and consistency violations and (2) methodological 
heterogeneity arising from the quality of the individual 
RCTs that make up the evidence network. The assess-
ment of clinical heterogeneity will be based on eval-
uation of the following data elements extracted from 
the RCTs:
a. The study design, including the quality of methods 
employed.
b. The admissibility criteria in terms of confounding 
factors (including subgroups of interest).
c. The measurement and reporting of outcomes (eg, 
definitions of progression and time points, testing 
assumptions for underlying distributions).
d. The comparators (common reference interven-
tion) and dosages, schedules and routes of admin-
istration.
2. The validity of an NMA of RWE by looking at the sim-
ilarity of patients populations across studies, similarity 
of treatments and differences in outcomes.
3. The use of complex statistical methods to control for 
confounding such as propensity score, disease risk 
score, and stabilised inverse probability weighting 
method.
Descriptive statistics will be conducted to describe the 
following:
 ► The main characteristics of the study populations at 
baseline (eg, age, sex, proportion of smokers, disease 
category as determined by the GOLD standard 
(A,B,C,D), FEV1 status, etc.)
 ► Study designs (eg, details specific to RCT and RWE).
 ► Whenever possible, graphs showing the characteris-
tics of studies by treatment or study will be developed. 
These findings will be used as a basis to identify poten-
tial sources of heterogeneity and to detect any poten-
tial outlier.
The problem of bias due to systematically differing 
entry criteria is not something we can pre-requisitely 
prevent; however, should there be large differences in 
population characteristics, we will conduct appropriate 
subgroup analyses.
network meta-analysis
This NMA will incorporate the scenarios of both indirect 
and mixed treatment comparisons. The NMA will initially 
trial in feasibility design whether RCTs can be compared 
solely with other RCT designs of similar methodology or 
whether other types of study design such as observational 
studies can be included in direct comparison. Heteroge-
neity and inconsistency will be tested using the Wald test 
for inconsistency.
Potential differences across studies may include:
 ► The treatment dose/schedule or outcome definitions 
(exacerbation description).
 ► The distribution of each study and patient 
characteristics.
 ► Baseline risks associated with each treatment.
 ► Observed treatment effects.
In order to account for these differences, methods of 
meta-regression, sub-group and sensitivity analysis may be 
employed.
Should it not be possible to compare all study designs 
in a single NMA to show best-efficacy ranking of interven-
tions, then separate NMAs will be performed for RCTs 
and the other study designs. The geometry of the network 
for each outcome measure will be presented in a network 
diagram of treatment nodes of variable sizes, comparison 
lines of variable thickness and loops to identify treatments 
with both direct and indirect comparisons.23
We plan to provide an overall combined ranking of 
interventions depending on their effect on exacerbation 
reduction compared with the combined weight of harm 
per intervention. Each harm will be weighted based on 
the severity of any harm reported as a result of using each 
intervention in each study. The study with best effect and 
least harm will be ranked first.
statistical analysis
Due to the nature of this NMA, it is assumed that a 
random effects meta-analysis model will be chosen for 
the primary outcome of rate of exacerbation and contin-
uous outcomes of health related quality of life and FEV1. 
To estimate patient years for exacerbations, deaths 
and adverse events we plan to use methods previously 
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reported.24 For change in continuous outcomes, that is, 
FEV1 and SGRQ, we will either use the reported change 
or calculate the change from baseline based on the 
reported values. We will calculate the SD of change from 
the reported standard errors or confidence intervals. The 
primary outcome of risk of exacerbation will be reported 
as rate ratio and other continuous outcome measures will 
be reported as mean differences assuming normal distri-
bution of data. The 95% CI for each summary statistics 
will be used to assess the statistical significance of each 
summary effect. The ranking of interventions will be 
based on their surface under cumulative ranking area, 
allowing clinicians to make treatment decisions based on 
relative effectiveness and risk of harm.25 Statistical anal-
ysis will be performed using Stata (StataCorp LP, College 
Station, TX, USA) and R (R Foundation for Statistical 
Computing, Vienna, Austria).
Confidence in cumulative evidence
The quality of evidence for our primary and secondary 
research questions will be assessed using those domains 
of the Grading of Recommendations, Assessment, Devel-
opment, and Evaluations (GRADE) guidelines that are 
pertinent to observational studies, notably those relating 
to methodological flaws within the component studies 
and the consistency of results across different studies. 
Additional domains may be considered if deemed appro-
priate. The strength of evidence will be judged as ‘high’ 
(further research is unlikely to change our conclusion), 
‘moderate’ (further research is likely to alter our conclu-
sion) or ‘low’ (further studies are required to answer the 
research question with a high degree of confidence/
increase confidence).
Patient involvement
No patients were involved in the design or analysis of this 
study.
EthICs And dIssEMInAtIOn
Ethical review is not required as this study is a system-
atic review. It is our intention to submit the results of 
our review for peer-reviewed publication and to present 
our findings at national and international meetings and 
conferences.
Contributors AL and ELA drafted the protocol and developed the inclusion/
exclusion criteria, the risk of bias assessment tool, the data extraction form 
and searching with guidance from JKQ. AL registered and updated the review 
on PROSPERO. AL, ELA, JP, RT, HV and JKQ contributed to the initial scoping 
discussions of the research, participated in decisions regarding the risk of bias 
assessment strategies and contributed to drafting the manuscript. JP provided 
guidance and contributed to the statistical plan. JKQ, AL and ELA participated in the 
protocol submission. JKQ is the guarantor of the review. 
Funding Boehringer Ingelheim Ltd. Bracknell, UK. Writing and research was 
funded by Boehringer Ingelheim Ltd; however, the publication of study results is not 
contingent on the sponsor's approval or censorship of the manuscript.
Competing interests AL was funded by Boehringer Ingelheim Ltd to perform this 
systematic review and network meta-analysis. ELA has nothing to declare. JP has 
nothing to declare. RT and HV are employees of Boehringer Ingelheim Ltd. JKQ’s 
research group has received funding from The Health Foundation, MRC, Wellcome 
Trust, BLF, GSK, Insmed, AZ and Bayer for other projects, none of which relate to 
this work. BI have funded this work. JKQ has received funds from AZ, GSK, Chiesi, 
Teva and BI for Advisory board participation or travel. 
Patient consent for publication Not required.
Provenance and peer review Not commissioned; externally peer reviewed.
Open access This is an open access article distributed in accordance with the 
Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which 
permits others to distribute, remix, adapt, build upon this work non-commercially, 
and license their derivative works on different terms, provided the original work is 
properly cited, appropriate credit is given, any changes made indicated, and the use 
is non-commercial. See: http:// creativecommons. org/ licenses/ by- nc/ 4. 0/.
rEFErEnCEs
 1. Rabe KF, Watz H. Chronic obstructive pulmonary disease. Lancet 
2017;389:1931–40.
 2. Appleton S, Poole P, Smith B, et al. Long-acting beta2-agonists for 
poorly reversible chronic obstructive pulmonary disease. Cochrane 
Database Syst Rev 2006;3:CD001104.
 3. Zhong N, Zheng J, Wen F, et al. Efficacy and safety of budesonide/
formoterol via a dry powder inhaler in Chinese patients with chronic 
obstructive pulmonary disease. Curr Med Res Opin 2012;28:257–65.
 4. Zheng JP, Yang L, Wu YM, et al. The efficacy and safety of 
combination salmeterol (50 microg)/fluticasone propionate (500 
microg) inhalation twice daily via accuhaler in Chinese patients with 
COPD. Chest 2007;132:1756–63.
 5. Karner C, Chong J, Poole P. Tiotropium versus placebo for chronic 
obstructive pulmonary disease. Cochrane Database Syst Rev 
2014:CD009285.
 6. Global initiative for chronic obstructive lung disease (GOLD), 2011.
 7. van Staa TP, Leufkens HG, Zhang B, et al. A comparison of cost 
effectiveness using data from randomized trials or actual clinical 
practice: selective cox-2 inhibitors as an example. PLoS Med 
2009;6:e1000194.
 8. Beeh KM, Beier J. The short, the long and the “ultra-long”: why 
duration of bronchodilator action matters in chronic obstructive 
pulmonary disease. Adv Ther 2010;27:150–9.
 9. Smeeth L, Douglas I, Hall AJ, et al. Effect of statins on a wide range 
of health outcomes: a cohort study validated by comparison with 
randomized trials. Br J Clin Pharmacol 2009;67:99–109.
 10. Rodrigo GJ, Price D, Anzueto A, et al. LABA/LAMA combinations 
versus LAMA monotherapy or LABA/ICS in COPD: a systematic 
review and meta-analysis. Int J Chron Obstruct Pulmon Dis 
2017;12:907–22.
 11. Zhu Y, Zhang T, Li H, et al. Discovering the Relative Efficacy 
of Inhaled Medications for Chronic Obstructive Pulmonary 
Disease: Multiple Treatment Comparisons. Cell Physiol Biochem 
2017;41:1532–46.
 12. Zheng JP, Wen FQ, Bai CX, et al. Twice daily N-acetylcysteine 600 
mg for exacerbations of chronic obstructive pulmonary disease 
(PANTHEON): a randomised, double-blind placebo-controlled trial. 
Lancet Respir Med 2014;2:187–94.
 13. Albert RK, Connett J, Bailey WC, et al. Azithromycin for prevention of 
exacerbations of COPD. N Engl J Med 2011;365:689–98.
 14. Bruguera-Avila N, Marin A, Garcia-Olive I, et al. Effectiveness of 
treatment with nebulized colistin in patients with COPD. Int J Chron 
Obstruct Pulmon Dis 2017;12:2909–15.
 15. Calverley PM, Rabe KF, Goehring UM, et al. Roflumilast in 
symptomatic chronic obstructive pulmonary disease: two 
randomised clinical trials. Lancet 2009;374:685–94.
 16. Excellence NIfHaC. Chronic obstructive pulmonary disease in over 
16s: diagnosis and management, 2010.
 17. GOLD. Global Strategy for the Diagnosis, Management and 
Prevention of COPD, Global Initiative for Chronic Obstructive Lung 
Disease (GOLD) 2017 [Webpage]. 2017 http:// goldcopd. org/ gold- 
2017- global- strategy- diagnosis- management- prevention- copd/ 
(accessed 10 Jan 2018).
 18. Shamseer L, Moher D, Clarke M, et al. Preferred reporting items for 
systematic review and meta-analysis protocols (PRISMA-P) 2015: 
elaboration and explanation. BMJ 2015;349:g7647.
 19. McGowan J, Sampson M, Salzwedel DM, et al. PRESS Peer Review 
of Electronic Search Strategies: 2015 guideline statement. J Clin 
Epidemiol 2016;75:40–6.
 20. Higgins JP, Altman DG, Gøtzsche PC, et al. The Cochrane 
Collaboration’s tool for assessing risk of bias in randomised trials. 
BMJ 2011;343:d5928.
 21. Program CAS. https:// casp- uk. net/ 2018
 on O









pen: first published as 10.1136/bm





7Lewis A, et al. BMJ Open 2019;9:e025048. doi:10.1136/bmjopen-2018-025048
Open access
 22. Peters JL, Sutton AJ, Jones DR, et al. Comparison of two 
methods to detect publication bias in meta-analysis. JAMA 
2006;295:676–80.
 23. Tonin FS, Rotta I, Mendes AM, et al. Network meta-analysis: a 
technique to gather evidence from direct and indirect comparisons. 
Pharm Pract 2017;15:943.
 24. Loymans RJ, Gemperli A, Cohen J, et al. Comparative effectiveness 
of long term drug treatment strategies to prevent asthma 
exacerbations: network meta-analysis. BMJ 2014;348:g3009.
 25. Mbuagbaw L, Rochwerg B, Jaeschke R, et al. Approaches to 
interpreting and choosing the best treatments in network meta-
analyses. Syst Rev 2017;6:79.
 on O









pen: first published as 10.1136/bm
jopen-2018-025048 on 20 F
ebruary 2019. D
ow
nloaded from
 
